BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Purchases 16,307 Shares of Hologic, Inc. (NASDAQ:HOLX)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 56.9% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,963 shares of the medical equipment provider’s stock after purchasing an additional 16,307 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Hologic were worth $3,339,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Innealta Capital LLC purchased a new stake in shares of Hologic during the second quarter valued at approximately $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic during the 1st quarter valued at $37,000. Cranbrook Wealth Management LLC bought a new stake in shares of Hologic in the 2nd quarter worth $47,000. Mather Group LLC. bought a new stake in shares of Hologic in the 1st quarter worth $48,000. Finally, Massmutual Trust Co. FSB ADV raised its stake in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock worth $54,000 after purchasing an additional 137 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Benjamin Jordan Cohn sold 5,093 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the sale, the insider now owns 10,476 shares in the company, valued at $858,927.24. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Brandon Schnittker sold 476 shares of the company’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $83.11, for a total transaction of $39,560.36. Following the transaction, the insider now owns 3,735 shares of the company’s stock, valued at approximately $310,415.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,280 shares of company stock worth $1,469,973. Corporate insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. lifted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Stephens reissued an “overweight” rating and set a $92.00 price objective on shares of Hologic in a report on Tuesday, July 30th. Evercore ISI raised their price target on Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research note on Tuesday, July 30th. Needham & Company LLC reissued a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday, September 17th. Finally, StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $87.60.

Hologic Stock Up 0.9 %

HOLX stock opened at $80.82 on Friday. The business’s 50-day moving average price is $81.08 and its 200-day moving average price is $77.27. The stock has a market cap of $18.86 billion, a P/E ratio of 41.23, a PEG ratio of 2.58 and a beta of 0.98. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.93 earnings per share. On average, equities research analysts forecast that Hologic, Inc. will post 4.09 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.